Czech entrepreneur builds Genome X lab to transform patient care

The founder of technology-and-medical group Channel Lab, David Navrátil, is developing a genetic lab in Czechia called Genome X, which aims to change the way patients are treated — instead of averaged-out treatment plans, doctors will get data on the specific person based on a detailed analysis of their DNA.

According to the entrepreneur, modern medicine too often targets the “statistically average patient,” even though no such person exists in biology. The same drug at the same dose can work perfectly for one person and prove useless or even harmful for another — largely because of genetic traits that affect things like liver function and how the body metabolizes medication.

Navrátil is convinced that genetics is exactly what can pull healthcare out of its vicious circle of “copy-paste treatment.” His team is already developing a free app called Molecula, which helps people spot dangerous combinations of medications, and plans to link it to genetic analysis data in the near future.

The topic, he says, is highly relevant: the population is aging, the number of chronically ill patients is growing, and according to projections, total healthcare spending in Czechia will exceed one trillion crowns a year by 2040. “That kind of pressure on the system can't be solved just by raising payroll contributions. We need effective, targeted prevention,” says Navrátil, a father of three sons, who admits that developing medical technology is also a personal matter for him — the question of what kind of healthcare system he wants to leave his children.

Genome X is built on whole genome sequencing (WGS) technology — unlike ordinary commercial DNA tests, which check only pre-selected sections of the genome, WGS “reads” a person's entire genome — all roughly three billion DNA “letters.” Navrátil compares this to the difference between skimming a book's table of contents and reading an entire encyclopedia closely: only complete data, interpreted in a clinical context, gives doctors a real chance to see a patient's full biological picture and spot risks early — before they turn into a costly, painful diagnosis.